Pharming Group N.V. (AMS:PHARM)
 1.120
 -0.010 (-0.88%)
  Nov 4, 2025, 11:37 AM CET
Pharming Group Revenue
Pharming Group had revenue of $93.22M USD in the quarter ending June 30, 2025, with 25.82% growth. This brings the company's revenue in the last twelve months to $339.84M, up 22.44% year-over-year. In the year 2024, Pharming Group had annual revenue of $297.20M with 21.15% growth.
Revenue (ttm) 
 $339.84M
Revenue Growth 
 +22.44%
P/S Ratio 
 2.68
Revenue / Employee 
 $841.18K
Employees 
 404
Market Cap 
774.22M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 297.20M | 51.88M | 21.15% | 
| Dec 31, 2023 | 245.32M | 39.69M | 19.30% | 
| Dec 31, 2022 | 205.62M | 6.75M | 3.39% | 
| Dec 31, 2021 | 198.87M | -13.30M | -6.27% | 
| Dec 31, 2020 | 212.17M | 22.79M | 12.03% | 
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPharming Group News
- 5 days ago - Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London - GlobeNewsWire
 - 12 days ago - Pharming Group to report third quarter 2025 financial results and provide business update on November 6 - GlobeNewsWire
 - 15 days ago - Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio - GlobeNewsWire
 - 4 weeks ago - Pharming Group provides update on previously announced G&A expense reduction plan - GlobeNewsWire
 - 4 weeks ago - FDA Accepts Pharming's SNDA For Leniolisib In Pediatric APDS; Priority Review Granted - Nasdaq
 - 4 weeks ago - Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years - GlobeNewsWire
 - 7 weeks ago - Pharming Group promoted to the Euronext AMX® index - GlobeNewsWire
 - 2 months ago - Pharming Group N.V. (PHAR) Presents at H.C. Wainwright 27th Annual Global Investment Conference - Slideshow - Seeking Alpha